Table 1 Demographics and baseline disease characteristics of csDMARD-IR patients included in the post hoc analysis
Demographic or baseline characteristica | Tofacitinib 5 mg BID + csDMARDs (N = 742) | Placebo + csDMARDs (N = 391) |
|---|---|---|
Age (years), mean (range) | 53.1 (18–86) | 52.4 (18–81) |
Female, n (%) | 625 (84.2) | 314 (80.3) |
Smoking, n (%) | ||
 Never smoked | 511 (68.9) | 260 (66.5) |
 Smoker | 96 (12.9) | 74 (18.9) |
 Ex-smoker | 135 (18.2) | 55 (14.1) |
Duration of RA (years), mean (range) | 8.0 (0.2–43.0) | 8.8 (0.3–49.4) |
DAS28-4(ESR) score, mean (SD) | 6.4 (1.0) | 6.3 (1.0) |
TJC, mean (SD) | 25.1 (14.7) | 24.7 (14.0) |
SJC, mean (SD) | 14.8 (9.2) | 14.8 (8.7) |
ESR (mm/h), mean (SD) | 50.1 (25.7) | 50.2 (24.6) |
RF-positive, n (%) | 630 (84.9) | 325 (83.1) |
PtGA VAS score (mm), mean (SD) | 58.3 (23.0) | 55.0 (22.5) |
Pain VAS score (mm), mean (SD) | 57.7 (23.0) | 55.2 (22.5) |
HAQ-DI score, mean (SD) | 1.4 (0.7) | 1.3 (0.7) |
FACIT-F score, mean (SD) | 29.0 (10.7) | 30.6 (10.2) |
SF-36 PCS score, mean (SD) | 33.1 (7.9) | 33.7 (7.5) |
SF-36 MCS score, mean (SD) | 40.6 (11.9) | 42.6 (11.5) |
MDGA VAS score, mean (SD) | 59.2 (16.9) | 58.0 (16.9) |
Concomitant therapy, n (%) | 742 (100.0) | 391 (100.0) |
 Oral corticosteroids, n (%) | 479 (64.6) | 246 (62.9) |
 Non-MTX csDMARDs, n (%) | 152 (20.5) | 75 (19.2) |
 MTX, n (%) | 677 (91.2) | 354 (90.5) |
 Concomitant MTX dose (mg), mean (range) | 14.3 (1.4–25.0) | 14.9 (1.0–25.0) |